Sequence of dsrna: atn-rna, intervention using irnai, use of a sequence of dsrna: atn-rna, a method of treating and inhibiting a brain tumor, a kit for inhibiting cancer cell which expresses tenascin, a method for a kit preparation in a brain tumor therapy

An intervention with RNA interference (iRNAi), characterised in that a fragment of tenascin-C mRNA is injected into a post-operative space wherein the double-stranded ATN-RNA (dsRNA) corresponds to the TN-C mRNA sequence at nucleotide positions 406-569, where the sequence is over 150 nucleotides long, with a complimentary RNA strand, wherein a sequence selected from among those presented in FIG. 1 is introduced into a post-operative space.

The use of a sequence of double-stranded ATN-RNA, containing a fragment of the tenascin-C mRNA sequence, characterised in that the double-stranded ATN-RNA (dsRNA) corresponds to the tenascin-C mRNA sequence at nucleotide positions 406-569, where the sequence is over 150 nucleotides long, with a complimentary RNA strand, and is used in the treatment of human brain tumors, wherein the ATN-RNA sequence causes a decrease in the expression of the tenascin-C gene, retarding tumor growth and wherein it relates to the treatment of other human neoplasma producing tenascin-C, preferably to brain tumors.

A method of treating a brain tumor which expresses tenascin-C, comprising removing a solid brain tumor expressing tenascin-C from an afflicted human subject, then forming an enclosed resection cavity at the location from which said solid brain tumor was removed, and then administering to said subject a fragment of the tenascin-C mRNA sequence at nucleotides 406 to 569 and forms a two-stranded ATN-RNA (dsRNA) with a complimentary RNA sequence, wherein a fragment with the complementary RNA is over 150 base pairs long, that binds to tenascin-C in a therapeutically effective amount.

A method for inhibiting brain tumor cell which expresses tenascin-C, comprising removing a solid brain tumor expressing tenascin-C from an afflicted human subject, then forming an enclosed resection cavity at the location from which said solid brain tumor was removed, and then administering to said subject a fragment of the tenascin-C mRNA sequence at nucleotides 406 to 569 and forms a two-stranded ATN-RNA (dsRNA) with a complimentary RNA sequence, wherein a fragment with the complementary RNA is over 150 base pairs long, that binds to tenascin-C in a therapeutically effective amount, and wherein the ATN-RNA sequence causes a decrease in the expression of the tenascin-C gene, and inhibition of tumor growth, and wherein the inhibiting cancer cell attachment and growth takes place in the brain.

A kit for use in inhibiting cancer cell which expresses tenascin-C, comprising reagents and components for use in treating a brain tumor, characterised in that it contains a fragment of the tenascin-C mRNA sequence at nucleotides 406 to 569 and forms a two-stranded RNA (dsRNA):

• ATN-RNA with a complimentary RNA sequence, wherein a fragment with the complementary RNA is over 150 base pairs long, that binds to tenascin-C in a therapeutically effective amount, wherein the ATN-RNA sequence in the kit causes a decrease in the expression of the tenascin-C gene, and inhibition of tumor growth.

A method for a kit preparation, wherein a kit is for use in inhibiting cancer cell which expresses tenascin, characterised in that, ATN-RNA is prepared by transcription of ATN-DNA with T7/T3 polymerases and is delivered directly into surgically created resection cavity of patients with malignant brain tumor, and wherein a plasmid harboring TN-C DNA is cleaved with HindIII or EcoRI, and ATN-RNA is synthesized in vitro with T7 and T3 RNA polimerases, and where a total RNA from brain, ovary and intestine tumor tissues is isolated and a reverse transcription is carried out and than the resultant cDNA is amplified with primers complementary to the tenascin-C and glyceraldehyde-3-phosphate dehydrogenase, GAPDH as an internal control in PCR reaction.

20-32. (canceled)